Video

Will Biosimilars Impact the Cost of Specialty Drugs?

Author(s):

Davy James, Managing Editor

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Related Videos
Lipoprotein particles | Image Credit: © komgritch - stock.adobe.com
Hands holding a crochet heart | Image Credit: © StockerThings - stock.adobe.com
Wooden blocks spelling HDL, LDL | Image Credit: © surasak - stock.adobe.com
Anticoagulant attacking blood clot | Image Credit: © BURIN93 - stock.adobe.com
Depiction of man aging | Image Credit: © Top AI images - stock.adobe.com
Map with pins | Image Credit: © Tryfonov - stock.adobe.com
Heart with stethoscope | Image Credit: © DARIKA - stock.adobe.com
Image Credit: © abricotine - stock.adobe.com
Senior Doctor is examining An Asian patient.
Related Content
Selma Mitchie, PharmD
November 21st 2024

Advancing Compounding Standards: Insights From the USP Compounding Implementation Workshop

Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer
October 28th 2024

Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer

Hidradenitis Suppurative, FDA, Dermatology, Bimzelx | Image Credit: © Gorodenkoff | stock.adobe.com
Published: November 20th 2024 | Updated: November 20th 2024

FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa

Ashley Gallagher, Associate Editor
Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment
September 26th 2024

Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment

Outpatient Transplant and CAR T-Cell Therapy: A Paradigm Shift in Care Delivery
November 19th 2024

Outpatient Transplant and CAR T-Cell Therapy: A Paradigm Shift in Care Delivery

Alana Hippensteele, Managing Editor
Sjogren Disease, FDA, Nipocalimab, Lupus, Rheumatoid Arthritis | Image Credit: © fizkes | stock.adobe.com
November 19th 2024

FDA Grants Breakthrough Therapy Designation for Nipocalimab to Treat Sjögren Disease

Ashley Gallagher, Associate Editor